Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Vanda ( (VNDA) ) has shared an announcement.
On February 18, 2025, Vanda Pharmaceuticals Inc. announced that its Compensation Committee had awarded 2024 annual bonuses and approved 2025 annual base salaries and bonus target amounts for its executive officers. The committee also granted restricted stock unit awards under the company’s equity incentive plan, with vesting beginning in 2026. This decision follows a review of executive compensation by a consultancy firm and impacts key company stakeholders by setting financial incentives and aligning executive interests with long-term company goals.
More about Vanda
Vanda Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of products for the treatment of central nervous system disorders.
YTD Price Performance: -5.60%
Average Trading Volume: 637,621
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $260.1M
For an in-depth examination of VNDA stock, go to TipRanks’ Stock Analysis page.
